These findings collectively emphasize the potential of multi-target strategies to enhance HER2-targeted therapies, potentially mitigating resistance mechanisms and improving therapeutic outcomes in HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.